Eliquis and Wound secretion - a phase IV clinical study of FDA data

Summary:

Wound secretion is reported as a side effect among people who take Eliquis (apixaban), especially for people who are female, 60+ old, have been taking the drug for 6 - 12 months also take Prolia, and have Crohn's disease.

The phase IV clinical study analyzes which people have Wound secretion when taking Eliquis. It is created by eHealthMe based on reports of 189,425 people who have side effects when taking Eliquis from the FDA, and is updated regularly.

What is Eliquis?

Eliquis has active ingredients of apixaban. It is often used in atrial fibrillation/flutter. eHealthMe is studying from 191,861 Eliquis users. Check the latest studies of Eliquis.

What is Wound secretion?

Wound secretion is found to be associated with 570 drugs and 759 conditions by eHealthMe. Check the latest studies of Wound secretion.

On Aug, 06, 2026

189,425 people reported to have side effects when taking Eliquis.
Among them, 45 people (0.02%) have Wound secretion.

Among these 45 people:

How long have people been on Eliquis when they have Wound secretion? *

What is the gender of people who have Wound secretion when taking Eliquis? *

female: 68.75 %
male: 31.25 %

What is the age of people who have Wound secretion when taking Eliquis? *

What are other drugs people take besides Eliquis? *

What are other side effects people have besides Wound secretion? *

Oedema Peripheral (superficial swelling): 20 people, 44.44%
Joint Pain: 19 people, 42.22%
Headache (pain in head): 19 people, 42.22%
Limb Injury: 14 people, 31.11%
Wound Complication: 14 people, 31.11%
Ecchymosis (a discoloration of the skin resulting from bleeding underneath): 12 people, 26.67%
Pain: 10 people, 22.22%
Drug Ineffective: 10 people, 22.22%
Scab (a hard coating on the skin formed during the wound healing): 10 people, 22.22%
Peripheral Swelling: 10 people, 22.22%

What are the existing conditions these people have? *

Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 13 people, 28.89%
Arrhythmias (irregular heartbeat): 7 people, 15.56%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 7 people, 15.56%
Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 4 people, 8.89%
Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 3 people, 6.67%
Gastric Ulcer (stomach ulcer): 2 people, 4.44%
Waldenstrom's Macroglobulinaemia (cancer affects small lymphocytes (white blood cells)): 2 people, 4.44%
Pyoderma Gangrenosum (ulcerating condition of skin that results in heaped borders with a typical appearance): 1 person, 2.22%
Hidradenitis (chronic disease of a type of sweat gland): 1 person, 2.22%
Bowel Movement Irregularity: 1 person, 2.22%

* Approximation only. Some reports may have incomplete information.

Do you take Eliquis and have Wound secretion?

- Check whether Wound secretion is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Eliquis:

Eliquis (191,861 reports)

Wound secretion treatments and more:

Wound secretion (5,127 reports)

Browse all side effects of Eliquis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Wound secretion:

Wound secretion (570 drugs)

Browse all the conditions that are associated with Wound secretion:

Wound secretion (759 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on apixaban (the active ingredients of Eliquis) and Eliquis (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.